BIRMINGHAM, Ala., June 30, 2014 /PRNewswire/ -- Atherotech Diagnostics Lab, a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions, announced today that its president and CEO, Michael V. Mullen, was awarded the Ernst & Young (EY) Entrepreneur of the Year Southeast program award for excellence in health care and life sciences. In May, Mullen was named one of the 24 finalists for the award, which recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. The Southeast program includes nominees from Alabama, Georgia, North Carolina, South Carolina and Tennessee, and eight categories with three nominees in each. The award gala was held at the InterContinental Buckhead Hotel in Atlanta, Georgia on Thursday, June 26.
"I am truly honored to be named the Southeast EY Entrepreneur of the Year for excellence in health care and life sciences," said Mullen. "Behind every leader is a great team of people and I think this is a true testament to Atherotech's commitment to delivering the most effective and cutting-edge technologies to ultimately reduce or eliminate heart disease. I look forward to many more successful years at Atherotech and thank EY for recognizing me with this amazing honor."
Mullen joined Atherotech Diagnostics more than ten years ago, serving in various roles, before being appointed to president and CEO in 2009. Prior to his role at Atherotech, Mullen began his career as a lab-technician at the University of Alabama-Birmingham and as an accountant for EY in the health care division. Mullen believes his EY experience prepared him for high-pressure situations and helped him lead the development and explosive growth that Atherotech has experienced since he took control. While at Atherotech, Mullen has dedicated his time to expanding awareness of the company's leading product, the VAP®+ Lipid Panel – the most comprehensive and accurate cholesterol assessment to enable an effective and personalized approach to improve health outcomes and, ultimately, save lives. Under Mullen's leadership, Atherotech has focused on building credible evidence to strengthen the company's position within the cardiovascular disease space. Last year proved to be highly successful, with the company adding 200 new employees and growth topping 40 percent over each of the last three years. In addition, Atherotech was named one of the "Top Companies to Work For" by the Birmingham Alabama Magazine in 2012.
The EY Entrepreneur of the Year Program is now in its 28th year and has expanded globally to recognize company builders in over 145 cities and in more than 60 countries worldwide. Regional award winners are automatically eligible to compete at the national level. Award recipients in several national categories, as well as the National EY Entrepreneur of the Year Overall Award winner, will be announced at the annual awards gala in Palm Springs, California, on November 15, 2014.
About EY Entrepreneur Of The Year™
EY Entrepreneur Of The Year is the world's most prestigious business award for entrepreneurs. The unique award makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement. As the first and only truly global award of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.
About Atherotech and the VAP®+ Lipid Panel
Atherotech Diagnostics Lab is a leading clinical reference laboratory specializing in cardiometabolic testing and disease management solutions. Atherotech's proprietary and comprehensive VAP®+ Lipid Panel enables clinicians to accurately stratify a patient's cardiovascular risk and deliver personalized treatment strategies to improve health outcomes. The Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines. The VAP+ utilizes direct measurement to identify cholesterol, triglyceride and genetic lipid disorders. The company's dedication to affordable, comprehensive disease management solutions includes Our Healthy Heart™, a patient consultation program and expert lipid management education service to health care providers. For more information, please visit www.Atherotech.com or call 1-866-VAP-TEST.
For information on the VAP+ Lipid Panel and Atherotech Diagnostics Lab, visit www.Atherotech.com or call 877-901-8510. Health care professionals interested in real cases from the trenches of lipidology may visit www.CobblesCorner.com, Atherotech's official blog. Atherotech is on Twitter at www.twitter.com/Atherotech, on Facebook at www.facebook.com/Atherotech, and broadcasting at www.YouTube.com/user/VAPatherotech.
SOURCE Atherotech Diagnostics Lab